Therapeutic interest in the GLP-1 signaling system has focused largely on its incretin (insulin-releasing) properties, and has culminated in the discovery of a novel diabetes therapy, Exendin-4 (EX4), a long-acting GLP-1 analogue [7]. This evidence concerns the gene GLP1R and diabetes mellitus.